We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+18.81%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$11.9M
Cap. Flow
+$29.8M
Cap. Flow %
6.53%
Top 10 Hldgs %
47.78%
Holding
85
New
14
Increased
34
Reduced
11
Closed
24

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$18M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$14.6M
3
VRNA
Verona Pharma
VRNA
+$6.28M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.17M
5
ASND icon
Ascendis Pharma A/S
ASND
+$6.11M

Top Sells

Rank Stock Value
1
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$14M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.84M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$6.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$6.4M
5
ADCT icon
ADC Therapeutics
ADCT
+$5.65M

Sector Composition

Rank Sector Weight
1 Healthcare 97.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NMRA icon
51
CALL
Neumora Therapeutics
NMRA
$306M
$1.56M 0.34%
+147,200
New +$1.76M
OLMA icon
52
Olema Pharmaceuticals
OLMA
$1.03B
$1.36M 0.3%
233,281
-221,801
-49% -$2.22M
GILD icon
53
Gilead Sciences
GILD
$163B
$924K 0.2%
+10,000
New +$900K
EYPT icon
54
EyePoint Inc
EYPT
$1.08B
$903K 0.2%
121,274
+21,274
+21% +$198K
RADX
55
Radiopharm Theranostics
RADX
$25.2M
$841K 0.18%
+187,406
New +$1.23M
ETNB
56
DELISTED
89bio
ETNB
$755K 0.17%
96,511
+4,213
+5% +$34.7K
VXRT
57
DELISTED
Vaxart
VXRT
$714K 0.16%
1,077,782
+77,782
+8% +$54K
KPTI icon
58
Karyopharm Therapeutics
KPTI
$159M
$403K 0.09%
39,733
+2,502
+7% +$30.3K
GUTS icon
59
Fractyl Health
GUTS
$109M
$364K 0.08%
176,922
+10,256
+6% +$23.9K
BIOA
60
BioAge Labs
BIOA
$1.1B
$231K 0.05%
39,974
-60,026
-60% -$1.04M
RCKTW icon
61
Rocket Pharmaceuticals Warrant
RCKTW
$342K
$3.6K ﹤0.01%
104,828
– –
ADCT icon
62
ADC Therapeutics
ADCT
$141M
– –
-1,795,080
Closed -$5.65M
ALGS icon
63
Aligos Therapeutics
ALGS
$26.7M
– –
-26,219
Closed -$227K
ALNY icon
64
Alnylam Pharmaceuticals
ALNY
$27.4B
– –
-35,774
Closed -$9.84M
APLT
65
DELISTED
Applied Therapeutics
APLT
– –
-100,000
Closed -$850K
BDTX icon
66
Black Diamond Therapeutics
BDTX
$98.6M
– –
-100,000
Closed -$435K
BHVN icon
67
Biohaven
BHVN
$2.08B
– –
-99,566
Closed -$4.98M
BIIB icon
68
Biogen
BIIB
$30.7B
– –
-19,940
Closed -$3.87M
BNTX icon
69
BioNTech
BNTX
$23.5B
– –
-26,083
Closed -$3.1M
CATX icon
70
Perspective Therapeutics
CATX
$341M
– –
-167,986
Closed -$2.24M
CCCC icon
71
CALL
C4 Therapeutics
CCCC
$405M
– –
-150,000
Closed -$855K
CRBP icon
72
CALL
Corbus Pharmaceuticals
CRBP
$168M
– –
-17,800
Closed -$367K
EVGN icon
73
Evogene
EVGN
$5.92M
– –
-307,974
Closed -$945K
MRSN
74
CALL
DELISTED
Mersana Therapeutics
MRSN
– –
-6,732
Closed -$318K
MRSN
75
DELISTED
Mersana Therapeutics
MRSN
– –
-63,431
Closed -$3M
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Silverarc Capital Management held 85 positions worth $457M, up 2.7% from $445M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $29.8M of net new capital in Q4 2024, opening 14 new positions and adding to 34 existing holdings. Its largest new stake was Pliant Therapeutics: 1,315,601 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Poseida Therapeutics, Inc. Common Stock, an estimated $14M trimmed.

  • Silverarc Capital Management's largest Q4 2024 buy was Pliant Therapeutics: 1,315,601 shares worth $17.3M.
  • Silverarc Capital Management added most to Syndax Pharmaceuticals in Q4 2024, an estimated $14.6M increase.
  • Silverarc Capital Management's biggest Q4 2024 reduction was Poseida Therapeutics, Inc. Common Stock, cutting an estimated $14M.
  • Silverarc Capital Management fully exited Alnylam Pharmaceuticals in Q4 2024, selling an estimated $9.84M.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $457M portfolio in Q4 2024.
  • Silverarc Capital Management opened 14 new positions and closed 24 in Q4 2024.
  • Silverarc Capital Management's portfolio value rose 2.7% quarter-over-quarter to $457M.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.